Genedx Holdings Corp. ( (WGS) ) has released its Q2 earnings. Here is a breakdown of the information Genedx Holdings Corp. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GeneDx Holdings Corp. is a genomic insights company focused on improving health outcomes through advanced exome and genome testing, primarily in the healthcare sector.
In its latest earnings report for the second quarter of 2025, GeneDx Holdings Corp. announced a significant increase in revenue, reaching $102.7 million, marking a 49% year-over-year growth. The company also reported a notable 69% growth in exome and genome test revenue, alongside an expanded adjusted gross margin of 71%.
Key financial highlights include an adjusted net income of $15.0 million, a stark improvement from the previous year’s adjusted net loss. The company has also raised its full-year revenue guidance to between $400 and $415 million, with expected growth in exome and genome revenue of 48% to 52%. Strategic developments include the American Academy of Pediatrics recommending exome and genome testing as first-line diagnostics for certain pediatric conditions, and the acquisition of Fabric Genomics to enhance global genomic insights delivery.
Looking forward, GeneDx remains optimistic about its growth trajectory, driven by expanding market access and strategic acquisitions. The company is poised to continue leveraging its genomic testing capabilities to transform healthcare from reactive to proactive care.